Comparison of molecular responses based on BCR-ABL1%^IS results from an in-house TaqMan-based qPCR versus Xpert^® assay in CML patients on tyrosine kinase inhibitor therapy

References

• Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–61.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423–32.
   PubMed Web of Science ®Google Scholar
• Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23:1957–63.
   PubMed Web of Science ®Google Scholar
• Winn-Deen ES, Helton B, Van Atta R, Wong W, Peralta J, Wang J, et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem. 2007;53:1593–600.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer Program. Leukemia. 2003;17:2318–57.
   PubMed Web of Science ®Google Scholar
• Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe Against Cancer Program. Leukemia. 2003;17:2474–86.
   PubMed Web of Science ®Google Scholar
• Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response comparison of response rates between clinical trials. Blood. 2008;112(8):3330–8.
   PubMed Web of Science ®Google Scholar
• Cross NC, Müller MC, Pane F, Hochhaus A, EUTOS Molecular Monitoring Steering Group. Working definitions of molecular response in CML. 2013.
   Google Scholar
• López-Jorge CE, Gómez-Casares MT, Jiménez-Velasco A, García-Bello MA, Barrios M, Lopez J, et al. Comparative study of BCR-ABL1 quantification: xpert assay, a feasible solution to standardization concerns. Ann Hematol. 2012;91:1245–50.
   PubMed Web of Science ®Google Scholar
• Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172–5.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841–51.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494–500.
   PubMed Web of Science ®Google Scholar
• Jobbagy Z, van Atta R, Murphy KM, Eshleman JR, Gocke CD. Evaluation of the Cepheid GeneXpert® BCR-ABL assay. J Mol Diagn. 2007;9(2):220–7.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett. 2014;347:22–8.
   PubMed Web of Science ®Google Scholar
• Melo JV, Yan XH, Diamond J, Lin F, Cross NC, Goldman JM. Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. Leukemia. 1996;10(7):1217–21.
   PubMed Web of Science ®Google Scholar